Navigation Links
Neurotez Engages Invictus Global Capital as Corporate Finance & Capital Markets Advisors

New York (PRWEB) October 07, 2014

Neurotez is proud to announce the engagement of Invictus Global Capital, Inc. to serve as the Company's corporate finance & capital markets advisor to assist in reviewing strategic options to meet the Company’s growth objectives and enhance shareholder value.

“We are thrilled with Invictus’ global outreach as an independent adviser and management partner, matching our efforts to expand in the markets globally (see our GCA Therapeutics deal). This group will provide Neurotez support in our efforts to grow the company and we anticipate working immediately and closely moving forward efficiently”, said Nikolaos Tezapsidis, President & CEO of Neurotez.

President & Managing Partner of Invictus Global Capital, Philip Brooks, said “As an early-stage biotechnology, Neurotez has been making exciting discoveries in the Alzheimer’s Disease space that not just address symptoms, but also provide therapeutic and curative solutions. With more than 5 million patients in the US alone, this is something that could have a very positive impact on so many lives and in so many families. We are delighted to be assisting Neurotez in advancing their strategy for growth towards commercialization. In addition to providing Neurotez with counsel on capital formation and structuring, we provide management with strategic support including drug development advisory that will lead to maximizing shareholder value.”

About Invictus Global Capital, Inc.

Invictus Global Capital Inc. is an independent corporate finance and capital markets advisory firm with offices in the British Virgin Islands, Toronto, New York City, and Zurich. Invictus specializes in strategic advisory support for technology company public offerings, capital formation, mergers & acquisitions, and corporate strategy. Our principal relationships are with high growth, innovation driven companies across full technology verticals from around the world. Please contact info(at)invictusipos(dot)com.

About Neurotez, Inc.

Neurotez, Inc. is a private Delaware corporation whose primary goal is to develop a recombinant human Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and as a preventative for those who are at risk. Their mission is to become world leaders in the advancement of AD therapy and prevention, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs that are both well tolerated and efficacious. The company sees several liquidity and exit options within the next few years. For investment inquires, please contact investorrelations(at)neurotez(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Immunomic Therapeutics Engages Newport Coast Securities, Inc.
2. BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
3. MRIGlobal Engages Industry Expert in Expansion of Molecular Diagnostic Division
4. NineSigma Engages AtriCure in the Ohio Third Frontier Open Innovation Incentive Program
5. Dicalcium Phosphate & Lithium Dihydrogen Phosphate Market (Global, China) Research Analysis Now Available at
6. Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz
7. Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
8. Global Specialty Enzymes Industry
9. Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019
10. Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at
11. Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc.
Post Your Comments:
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. (Nasdaq: ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ... strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
Breaking Biology Technology:
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/10/2020)... ... , ... Today CJ BIO announced the first in a series of Food ... phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range ... 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test ... 16 minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the detection ...
Breaking Biology News(10 mins):